

1 Associations of comorbidities and medications with COVID-19 2 outcome: A retrospective analysis of real-world evidence data

3 Authors

4 Basel Abu-Jamous^{1,#}, Arseni Anisimovich^{1,#}, Janie Baxter¹, Lucy Mackillop^{1,2,3}, Marcela P.
5 Vizcaychipi^{4,5}, Alex McCarthy⁴, Rabia T. Khan^{1,*}

6 Affiliations

7 ¹Sensyne Health plc, Schrodinger Building, Heatley Road, Oxford Science Park, Oxford,
8 OX4 4GE.

9 ²Oxford University Hospitals NHS Foundation Trust, Women's Centre, John Radcliffe
10 Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK.

11 ³Nuffield Department of Women's and Reproductive Health, University of Oxford, Women's
12 Centre, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK.

13 ⁴Chelsea and Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London,
14 SW10 9NH, UK.

15 ⁵Academic Department of Anaesthesia & Intensive Care Medicine, Imperial College London,
16 Chelsea & Westminster Campus, 369 Fulham Road, London, SW10 9NH, UK.

17

18 # Joint first author

19 * Corresponding author

20 Correspondence address

21 Rabia Tahir Khan

22 Sensyne Health plc, Schrodinger Building, Heatley Road, Oxford Science Park, Oxford,
23 OX4 4GE

24 Email: rabia.khan@sensynehealth.com

25 Keywords

26 COVID-19, electronic healthcare records, comorbidities, medications, mortality

27 Running title

28 Associations of comorbidities and medications with COVID-19 outcome

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 Abstract

30 **Background** Hundreds of thousands of deaths have already been recorded for
31 patients with the severe acute respiratory syndrome coronavirus (SARS-CoV-2; aka
32 COVID-19). Understanding whether there is a relationship between comorbidities
33 and COVID-19 positivity will not only impact clinical decisions, it will also allow an
34 understanding of how better to define the long-term complications in the groups at
35 risk. In turn informing national policy on who may benefit from more stringent social
36 distancing and shielding strategies. Furthermore, understanding the associations
37 between medications and certain outcomes may also further our understanding of
38 indicators of vulnerability in people with COVID-19 and co-morbidities.

39 **Methods** Electronic healthcare records (EHR) from two London hospitals were
40 analysed between 1st January and 27th May 2020. 5294 patients presented to the
41 hospitals in whom COVID status was formally assessed; 1253 were positive for
42 COVID-19 and 4041 were negative. This dataset was analysed to identify
43 associations between comorbidities and medications, separately and two
44 outcomes: (1) presentation with a COVID-19 positive diagnosis, and (2) inpatient
45 death following COVID-19 positive diagnosis. Medications were analysed in
46 different time windows of prescription to differentiate between short-term and long-
47 term medications. All analyses were done with controls (without co-morbidity)
48 matched for age, sex, and number of admissions, and a robustness approach was
49 conducted to only accept results that consistently appear when the analysis is
50 repeated with different proportions of the data.

51 **Results** We observed higher COVID-19 positive presentation for patients with
52 hypertension (1.7 [1.3-2.1]) and diabetes (1.6 [1.2-2.1]). We observed higher
53 inpatient COVID-19 mortality for patients with hypertension (odds ratio 2.7 [95% CI
54 1.9-3.9]), diabetes (2.2 [1.4-3.5]), congestive heart failure (3.1 [1.5-6.4]), and renal
55 disease (2.6 [1.4-5.1]). We also observed an association with reduced COVID-19
56 mortality for diabetic patients for whom anticoagulants (0.11 [0.03-0.50]), lipid-
57 regulating drugs (0.15 [0.04-0.58]), penicillins (0.20 [0.06-0.63]), or biguanides (0.19
58 [0.05-0.70]) were administered within 21 days after their positive COVID-19 test with

59 no evidence that they were on them before, and for hypertensive patients for whom
60 anticoagulants (0.08 [0.02-0.35]), antiplatelet drugs (0.10 [0.02-0.59]), lipid-
61 regulating drugs (0.15 [0.05-0.46]), penicillins (0.14 [0.05-0.45]), or angiotensin-
62 converting enzyme inhibitors (ARBs) (0.06 [0.01-0.53]) were administered within 21
63 days post-COVID-19-positive testing with no evidence that they were on them
64 before. Moreover, long-term antidiabetic drugs were associated with reduced
65 COVID-19 mortality in diabetic patients (0.26 [0.10-0.67]).

66 **Conclusions** We provided real-world evidence for observed associations between
67 COVID-19 outcomes and a number of comorbidities and medications. These results
68 require further investigation and replication in other data sets.

69 Introduction

70 As of the 16th of August 2020, the COVID-19 pandemic has resulted in more than
71 770,000 deaths worldwide over the course of a few months. Although most of the
72 confirmed cases of COVID-19 infection show mild or no symptoms, a global
73 concern exists in ensuring that healthcare systems can cope with those that require
74 hospitalisation, especially with the coming winter pressure and while preparing for a
75 potential second wave. Correct identification of individuals with higher risk of
76 presentation or of death due to COVID-19 will not only help hospitals better identify
77 those in need of hospitalisation but will also assist the community in identifying the
78 vulnerable who require more careful shielding.

79 Hypertension and diabetes have been shown to be associated with poorer outcome
80 in COVID-19. (Perico, et al., 2020). Furthermore, it has been postulated that certain
81 medications may modulate the immune response to COVID-19 infection, positively
82 or negatively.

83 We have set out to investigate the association of comorbidities and medications
84 with either presentation with COVID-19 positive diagnosis or death due to COVID-
85 19 in a real-world-evidence (RWE) dataset.

86 Methods


87 *The dataset*

88 Electronic health record (EHR) data were obtained from the Chelsea & Westminster
89 Hospital NHS Foundation Trust for 5294 patients presented to the Trust's
90 hospitals between 1st January and 27th May 2020. The patient population consisted
91 of 1253 COVID-19 positive and 4041 COVID-19 negative patients as diagnosed
92 using viral PCR from swap tests.

93 For these 5294 patients the dataset included patients' history of primary and
94 secondary diagnoses recorded in the hospital (from 2004 to 2020) medications
95 administered or prescribed in the hospital (from 2010 to 2020), and death status.

96 *Association analysis of comorbidities with COVID-19 presentation and mortality*

97 We examined the association of comorbidities with COVID-19 positive presentation
 98 as well as with inpatient mortality of COVID-19 patients. This is realised by using
 99 Fisher’s exact test to compare the outcomes of patients with a given comorbidity
 100 (the active arm) and patients without that comorbidity (the control arm). To account
 101 for possible confounders, the two arms were matched on age, sex, and the number
 102 of admissions of patients in their available history (Figure 1 (b)). To reduce false
 103 discoveries, multiple hypothesis testing was conducted using the Benjamini
 104 Hochberg (BH) method. Furthermore, a robustness analysis was carried out by
 105 running the same test experiment once with 100% of the available data and 20
 106 more times with randomly selected proportions (60%, 70%, 80%, or 90%) of the
 107 data. An association is considered significant if its adjusted p-value was smaller
 108 than 0.05 in more than 70% of these individual experiments (Figure 1 (a)).



109

110 **Figure 1. Statistical analysis pipeline.** (a) For each tested comorbidity or medication, a total of 21
 111 tests of association are conducted with different proportions of the dataset. The tested association is
 112 considered significant if $p \leq 0.05$ in more than 70% of the tests. (b) Each line of analysis is
 113 conducted on active and control arms that are matched on age, sex, and number of admissions.
 114 Odds-ratios (OR) and 95% confidence intervals (CI) are calculated only if the active arm included
 115 more than 10 patients; otherwise, the test yields no result.

116 Patients are included in the active arm if a record of the given disease appears at
 117 least once in their available history. Disease diagnoses are recorded in our data
 118 using the International Classification of Diseases, tenth revision (ICD-10) codes.
 119 ICD-10 codes were translated into 19 disease groups following the approach

120 proposed by (Quan, et al., 2005) with some amendments ensuring that hypertension
121 and asthma were individually assessed in the analysis (Table 1).

122 *Table 1. ICD-10 codes used for comorbidity grouping from (Quan, et al., 2005)**


Disease group	ICD-10 codes
Myocardial infarction	I21, I22, I252
Congestive heart failure	I43, I50, I099, I110, I130, I132, I255, I420, I425, I426, I427, I428, I429, P290
Peripheral vascular disease	I70, I71, I731, I738, I739, I771, I790, I792, K551, K558, K559, Z958, Z959
Cerebrovascular disease	G45, G46, I60, I61, I62, I63, I64, I65, I66, I67, I68, I69, H340
Dementia	F00, F01, F02, F03, G30, F051, G311
Chronic pulmonary disease excluding asthma*	J40, J41, J42, J43, J44, J46, J47, J60, J61, J62, J63, J64, J65, J66, J67, I278, I279, J684, J701, J703
Asthma*	J45
Connective tissue disease rheumatic disease	M05, M32, M33, M34, M06, M315, M351, M353, M360
Peptic ulcer disease	K25, K26, K27, K28
Mild liver disease	B18, K73, K74, K700, K701, K702, K703, K709, K717, K713, K714, K715, K760, K762, K763, K764, K768, K769, Z944
Diabetes	E100, E101, E106, E108, E109, E110, E111, E116, E118, E119, E120, E121, E126, E128, E129, E130, E131, E136, E138, E139, E140, E141, E146, E148, E149, E102, E103, E104, E105, E107, E112, E113, E114, E115, E117, E122, E123, E124, E125, E127, E132, E133, E134, E135, E137, E142, E143, E144, E145, E147
Paraplegia and hemiplegia	G81, G82, G041, G114, G801, G802, G830, G831, G832, G833, G834, G839
Renal disease	N18, N19, N052, N053, N054, N055, N056, N057, N250, I120, I131, N032, N033, N034, N035, N036, N037, Z490, Z491, Z492, Z940, Z992
Metastatic carcinoma	C77, C78, C79, C80
Cancer	C00, C01, C02, C03, C04, C05, C06, C07, C08, C09, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C30, C31, C32, C33, C34, C37, C38, C39, C40, C41, C43, C45, C46, C47, C48, C49, C50, C51, C52, C53, C54, C55, C56, C57, C58, C60, C61, C62, C63, C64, C65, C66, C67, C68, C69, C70, C71, C72, C73, C74, C75, C76, C81, C82, C83, C84, C85, C88, C90, C91, C92, C93, C94, C95, C96, C97
Moderate or severe liver disease	K704, K711, K721, K729, K765, K766, K767, I850, I859, I864, I982
Aids (HIV)	B20, B21, B22, B24
Hypertension*	I10, I11, I12, I13, I15

* These disease groups have been changed from what is proposed in (Quan, et al., 2005). The two changes are splitting the “Chronic pulmonary disease” group into “Chronic pulmonary disease excluding asthma” and “Asthma” and adding the “Hypertension” group.

123 *Analysis of association of medications with COVID-19 presentation and mortality*

124 We investigated the association of pharmacological therapy with COVID-19 positive
125 presentation and inpatient mortality in COVID-19 patients. To assess the
126 association of a given medication with these end points, we utilised the same
127 stringent statistical approach that was described above for the comorbidities
128 analysis, including matching on age, sex, and number of admissions, as well as the
129 robustness analysis with different proportions of the full dataset (Figure 1).
130 However, two further aspects were considered in this analysis; the first was
131 conditioning on comorbidities; that is, the association of each medication with end


132 points was assessed separately for patients with different comorbidities (Figure 2).
133 This is to reduce the possibility of confounding observed association of medications
134 with outcomes by their association with diseases. The definitions of comorbidity
135 ICD-10 codes were based on Table 1.



137 **Figure 2. Analysis of medications was performed after conditioning on comorbidities.**

138 The second aspect was the incorporation of the time of prescription. This is
139 because the effects of medications can be dependent on the time of admission.
140 Figure 3 illustrates the six lines of analysis that were conducted separately for each
141 medication conditioned on comorbidities. The lines of analysis were designed to
142 handle short-term and long-term medications differently. We define a short-term
143 medication as a medication that was prescribed to the patient within the short
144 period of time of indicated in Figure 3 but never before that (Figure 3: PP-ST1, PP-
145 ST2, M-ST1, and M-ST2). As for long-term medications, they are defined as those
146 which were prescribed at least twice in the patient history, one of which is more
147 recent (Figure 3: PP-LT and M-LT). In all of these lines of analysis, medications with
148 no more than ten patients in their active arm were skipped.

149 Medications were encoded using British National Formulary (BNF) codes. BNF
150 codes form a hierarchy where medications are classified into *BNF chapters*, which
151 are sub-classified into *BNF sections*, which in turn are classified into *BNF*
152 *paragraphs*, and so on up to eight levels of depth. In most of the cases, medications
153 in our dataset are recorded with codes up to three or four levels of depth. When
154 counting data records of a given BNF code, all medications of codes in deeper
155 hierarchy levels are counted as well.




156

157 **Figure 3. Lines of analysis of medications' association with COVID-19 positive presentation or**
 158 **inpatient mortality in COVID-19 patients.** The identifiers (IDs) for these lines of analysis are coded
 159 by a reference to the considered end point (PP: COVID-19 positive presentation; M: mortality) and a
 160 reference to the temporal consideration of the tested medications (ST: short-term; LT: long-term). If
 161 two lines of analysis share the same end point and temporal consideration, they are numbered with
 162 ordinal numbers.

163 **Results**

164 *Characteristics of the dataset*

165 Figure 4 shows that the COVID-19 positive cohort has higher median age, more
 166 males, and patients with more hospital admissions than the COVID-19 negative
 167 cohort. A similar trend also appears in the cohort of deceased COVID-19 patients
 168 compared to the cohort of COVID-19 patients with no observed death in hospital
 169 (Figure 4).



170

171 *Figure 4. Distributions of age (a, b), sex (c, d), and number of admissions in patient's history (e, f),*
 172 *each in COVID-19 positive versus negative patients (a, c, e), and in COVID-19 positive deceased*
 173 *versus survived patients (b, d, f). Calculation of p values was done using the unpaired two-sided*
 174 *Wilcoxon rank-sum test for age and number of admissions distributions (a, b, e, f), and using the two-*
 175 *sided Fisher's exact test for sex distribution (c, d).*

176 *Association of comorbidities with COVID-19 presentation and mortality*

177 We observed that the comorbidities of hypertension and diabetes have statistically
 178 significant associations with the diagnosis of COVID-19 (Table 2). Moreover,
 179 hypertension, diabetes, congestive heart disease, and renal disease show
 180 significant association with higher inpatient mortality in COVID-19 patients (Table 3).
 181 These results were obtained after controlling for the effect of age, sex, and number
 182 of admissions in patients' history.

183 Table 2. Comorbidity association with presentation with COVID-19 positive diagnosis

Disease group	Does not have disease		Have disease		$\overline{OR} (\overline{CI})^*$	POSE [#]
	CODIV-19 Negative	COVID-19 Positive	CODIV-19 Negative	COVID-19 Positive		
Hypertension	703	280	606	377	1.66 (1.33-2.07)	90%
Diabetes	339	183	294	228	1.55 (1.16-2.07)	71%
Dementia	126	66	112	80	1.52 (0.94-2.47)	14%
Cancer	120	84	143	61	0.61 (0.38-0.97)	10%
Chronic pulmonary disease excluding asthma	150	113	177	86	0.74 (0.49-1.12)	5%
Congestive heart failure	156	86	158	84	0.91 (0.59-1.40)	0%
Asthma	197	102	192	107	1.12 (0.76-1.66)	0%
Mild liver disease	91	27	89	29	0.73 (0.38-1.42)	0%
Connective tissue disease rheumatic disease	42	15	40	17	1.27 (0.48-3.34)	0%
Peptic ulcer disease	50	29	52	27	0.98 (0.46-2.08)	0%
Paraplegia and hemiplegia	50	27	51	26	0.86 (0.40-1.85)	0%
Renal disease	145	105	151	99	0.95 (0.63-1.44)	0%
Peripheral vascular disease	81	31	74	38	1.04 (0.54-1.99)	0%
Metastatic carcinoma	44	24	51	17	0.57 (0.24-1.34)	0%
Cerebrovascular disease	146	103	161	88	0.85 (0.56-1.29)	0%
Myocardial infarction	140	99	160	79	0.74 (0.48-1.14)	0%
Moderate or severe liver disease [§]	Low number [§]	Low number [§]	Low number [§]	Low number [§]	NA [§]	NA [§]
Aids (HIV) [§]	Low number [§]	Low number [§]	Low number [§]	Low number [§]	NA [§]	NA [§]

* \overline{OR} is the geometric mean of the odds ratios obtained from the 21 robustness experiments run with different proportions of data as demonstrated in Figure 1 (a). \overline{CI} is the 95% confidence interval where its limits were calculated using the geometric means of the CI limits of the aforementioned 21 robustness experiments.
 # POSE: the percentage of significant experiments; that is, the percentage of experiments run over different proportions of data that yielded a significant p-value of 0.05 or smaller. This is a measure of robustness.
 § Very small numbers of patients were available for these comorbidities and therefore statistics are not applicable (NA).

184 Table 3. Comorbidity association with mortality of COVID-19 positive patients

Disease group	Does not have disease		Have disease		$\overline{OR} (\overline{CI})^*$	POSE [#]
	Survived	Deceased	Survived	Deceased		
Hypertension	294	83	214	163	2.70 (1.87-3.92)	100%
Diabetes	176	52	127	101	2.20 (1.38-3.49)	95%
Congestive heart failure	57	27	35	49	3.05 (1.45-6.41)	81%
Renal disease	61	38	40	59	2.63 (1.35-5.13)	76%
Cerebrovascular disease	59	29	44	44	2.09 (1.02-4.29)	38%
Myocardial infarction	47	32	35	44	2.13 (1.01-4.49)	24%
Peripheral vascular disease	27	11	17	21	3.29 (1.04-10.4)	19%
Dementia	47	33	35	45	1.89 (0.90-3.96)	14%
Metastatic carcinoma	10	7	5	12	4.56 (0.79-26.3)	10%
Cancer	36	25	31	30	1.61 (0.69-3.76)	5%
Peptic ulcer disease	16	11	14	13	1.61 (0.44-5.87)	5%

Chronic pulmonary disease excluding asthma	46	40	43	43	1.65 (0.81-3.36)	0%
Asthma	73	34	69	38	1.20 (0.62-2.32)	0%
Mild liver disease	22	7	20	9	1.04 (0.27-3.98)	0%
Paraplegia and hemiplegia	16	10	16	10	1.50 (0.38-5.88)	0%
Connective tissue disease rheumatic disease	10	7	12	5	0.57 (0.10-3.24)	0%
Moderate or severe liver disease[§]	Low number [§]	Low number [§]	Low number [§]	Low number [§]	NA [§]	NA [§]
Aids (HIV)[§]	Low number [§]	Low number [§]	Low number [§]	Low number [§]	NA [§]	NA [§]

* \overline{OR} is the geometric mean of the odds ratios obtained from the 21 robustness experiments run with different proportions of data as demonstrated in Figure 1 (a). \overline{CI} is the 95% confidence interval where its limits were calculated using the geometric means of the CI limits of the aforementioned 21 robustness experiments.

POSE: the percentage of significant experiments; that is, the percentage of experiments run over different proportions of data that yielded a significant p-value of 0.05 or smaller. This is a measure of robustness.

§ Very small numbers of patients were available for these comorbidities and therefore statistics are not applicable (NA).

185 *Association of medications with COVID-19 presentation and mortality*

186 Table 4 shows the numbers of medications qualified for testing in each line of
 187 analysis given that they were prescribed to more than 10 patients within the relevant
 188 time window (Figure 3). This table also shows the number of medications, out of all
 189 of those qualified for testing, that showed significant and robust association with
 190 reduced presentation with COVID-19 (lines PP-ST1, PP-ST2, and PP-LT) or with
 191 reduced inpatient mortality in COVID-19 patients (lines M-ST1, M-ST2, and M-LT).

192 *Table 4. Summary of numbers of medications qualified for testing in each one of the six lines of*
 193 *analysis and numbers of medications with significant association with reduced COVID-19 positive*
 194 *presentation or with reduced mortality in COVID-19 patients.*

Line of analysis ID	Medications qualified for testing (those with more than 10 patients in their active arm)			Medications associated with reduced COVID-19 positive presentation (PP- lines) or with reduced mortality (M- lines)		
	BNF Sections	BNF paragraphs	BNF sub-paragraphs	BNF Sections	BNF paragraphs	BNF sub-paragraphs
PP-ST1	21	18	5	0	0	0
PP-ST2	22	19	5	0	0	0
PP-LT	112	53	10	0	0	0
M-ST1	53	37	10	10	7	2
M-ST2	50	36	10	11	6	1
M-LT	60	27	5	1	0	0

195 None of the tested medications was significantly and robustly associated with
 196 reduced COVID-19 presentation in our results, whether while considering short-
 197 term medications (PP-ST1 and PP-ST2) or long-term medications (PP-LT). Results
 198 with different thresholds of robustness are provided in Supplementary File S1.

Table 5. Statistically significant and robust associations between medications and mortality for COVID-19+ patients. The full list of tested medications is included in Supplementary File S1.

Disease group	Drug BNF code / drug name	Not on Medication		On Medication		\bar{OR} (\bar{CI})*	POSE#
		Survived	Deceased	Survived	Deceased		
Intersection of M-ST1 and M-ST2^s							
Diabetes	02.08.02 Oral Anticoagulants	72	96	21	3	0.11 (0.03-0.50)	100%
	02.12 Lipid-Regulating Drugs	70	90	22	4	0.15 (0.04-0.58)	86%
	05.01.01.03 Broad-Spectrum Penicillins	73	94	24	5	0.20 (0.06-0.64)	90%
	06.01.02.02 Biguanides	74	94	19	4	0.19 (0.05-0.70)	81%
Hypertension	01.03 Antisecretory Drugs+Mucosal Protectants	120	148	31	9	0.22 (0.09-0.56)	100%
	01.06 Laxatives	129	153	21	3	0.10 (0.02-0.45)	95%
	02.05.05.01 Angiotensin-Converting Enzyme Inhibitors	140	160	17	1	0.06 (0.01-0.53)	81%
	02.06.02 Calcium-Channel Blockers	122	154	33	5	0.12 (0.04-0.36)	100%
	02.08.01 Parenteral Anticoagulants	144	160	19	2	0.09 (0.02-0.50)	90%
	02.08.02 Oral Anticoagulants	122	153	27	3	0.08 (0.02-0.35)	100%
	09.02 Antiplatelet Drugs	139	158	16	2	0.10 (0.02-0.59)	95%
	02.12 Lipid-Regulating Drugs	118	148	33	6	0.15 (0.05-0.46)	95%
	04.07.01 Non-Opioid Analgesics And Compound Prep	136	152	19	5	0.22 (0.07-0.69)	76%
	05.01.01.03 Broad-Spectrum Penicillins	131	156	29	5	0.14 (0.05-0.45)	100%
M-ST1 other than those that also appeared in M-ST2							
None							
M-ST2 other than those that also appeared in M-ST1							
Diabetes	02.05 Hypertension and Heart Failure	79	92	14	3	0.15 (0.03-0.66)	71%
	02.06 Nit,Calc Block & Other Antianginal Drugs	79	96	14	2	0.11 (0.02-0.60)	86%
Hypertension	02.02 Diuretics	134	151	21	8	0.33 (0.12-0.91)	81%
	02.04 Beta-Adrenoceptor Blocking Drugs	134	152	19	7	0.29 (0.10-0.86)	86%
M-LT							
Diabetes	06.01 Drugs Used In Diabetes	30	65	26	12	0.26 (0.10-0.67)	71%

* \bar{OR} is the geometric mean of the odds ratios obtained from the 21 robustness experiments run with different proportions of data as demonstrated in Figure 1 (a). \bar{CI} is the 95% confidence interval where its limits were calculated using the geometric means of the CI limits of the aforementioned 21 robustness experiments.

POSE: the percentage of significant experiments; that is, the percentage of experiments run over different proportions of data that yielded a significant p-value of 0.05 or smaller. This is a measure of robustness.

\$ Medications of significant association with reduced mortality in both M-ST1 and M-ST2. Numbers of patients as well as \bar{OR} and \bar{CI} values shown in this table are as reported in the results of the M-ST2 line.

201 Table 5 lists medications that passed the test of robust statistical significance.
202 Where a BNF section and one of its BNF paragraphs both appear significant, the
203 one that is less specific is omitted from this table for a more concise display.
204 Nonetheless, all tested medications are listed in Supplementary File S2.

205 Considering short-term medications (M-ST1 & M-ST2), we observed an association
206 with lower COVID-19 mortality for both diabetic and hypertensive patients for whom
207 anticoagulants, lipid-regulating drugs, and penicillins were administered after their
208 positive COVID-19 test (Table 5).

209 Biguanides prescribed to diabetic patients after testing positive on COVID-19 were
210 associated with reduced mortality (Table 5). Interestingly, the more general BNF
211 section of drugs used in diabetes, which includes insulins as well as antidiabetic
212 drugs, showed association with reduced COVID-19 mortality for diabetic patients
213 for whom there is an evidence of prescription before and after a positive COVID-19
214 test (M-LT) (Table 5).

215 Furthermore, angiotensin-converting enzyme inhibitors (ARBs) and antiplatelet
216 drugs showed association with reduced COVID-19 mortality when administered to
217 hypertensive patients after testing positive on COVID-19 (M-ST1 & M-ST2) (Table 5).

218 Discussion

219 We describe the retrospective analysis of 5294 patients presenting to two hospitals
220 in London; 1253 of whom were COVID-19 positive. We observe that having a
221 diagnosis of hypertension or diabetes was associated with a higher presentation
222 with COVID-19, and that hypertension, diabetes, congestive heart failure, and renal
223 disease were associated with a higher chance of in-hospital death for COVID-19
224 positive patients. Furthermore, we observe associations between a number of
225 medications prescribed after a positive COVID-19 test and reduced mortality;
226 examples include anticoagulants, lipid-regulating drugs, and penicillins for diabetic
227 and hypertensive patients, biguanides for diabetic patients, and ARBs and
228 antiplatelets drugs for hypertensive patients. We also observed an association with

229 reduced COVID-19 mortality for diabetic patients who have been on diabetic drugs
230 even before testing positive on COVID-19.

231 Co-morbidities associated with COVID-19 have been reported previously in the
232 literature for a number of diseases such as hypertension (Williams & Zhang, 2020;
233 Vizcaychipi, et al., 2020), renal diseases, and diabetes (Wu & McGoogan, 2020;
234 Chen, et al., 2020; Yang, et al., 2020; Wang, et al., 2020; Perico, et al., 2020;
235 Vizcaychipi, et al., 2020). COVID-19 patients with such co-morbidities were more
236 likely to present to hospital which is in line with many NHS triage systems who
237 recognise this group as vulnerable and therefore are more likely to recommend
238 hospital attendance.

239 Some of our observations of associations of medications are in-line with published
240 literature, such as the protective effect of anticoagulants patients on COVID-19
241 outcomes (Atallah, et al., 2020; Tang, et al., 2020). On the other hand, some of our
242 observations on medications were at odds with the published literature or published
243 literature gave conflicting results, such as the effect of ARBs (Perico, et al., 2020;
244 Cure & Cure, 2020a; Cure & Cure, 2020b).

245 For all lines of analyses of comorbidities and medications, matching active and
246 control arms on age, sex, and number of admissions was essential to account for
247 substantial confounding factors. The essence of this is indicated by observing that
248 the distributions of these covariates differed significantly between patients who had
249 positive and negative COVID-19 test results as well as between COVID-19 patients
250 who died and who did not (Figure 4). Matching the number of hospital admissions
251 aims at comparing patients with more comparable medical history and overall
252 health condition.

253 *Limitations*

254 Observed associations should be interpreted with care as they might be attributable
255 to confounding factors. For example, we did not use measures of functional status,
256 e.g. clinical fragility scale, which may have been over-represented in one arm of our
257 analysis. Furthermore, we have not considered interactions between multiple co-

258 morbidities and their association with outcomes. Severity of COVID-19 infection at
259 presentation was not incorporated and no distinction is being made in this analysis
260 between those who have been admitted for an acute episode of some comorbidity
261 in their most recent admission and those who have not despite having that
262 condition chronically. Also, length of symptoms at point of presentation to hospital
263 were not assessed neither was the frailty scale.

264 Observations in this study are based on a population of patients presenting to
265 hospitals and for whom COVID-19 status has been assessed to be positive or
266 negative. This may cause a bias as it is not comparing individuals belonging to the
267 general community population. Also, this population of patients comes from two
268 London metropolitan hospitals that may not have a similar distribution of
269 comorbidities and features as hospitals in other metropolitan cities or hospitals
270 away from large cities. Generalisability is therefore not assured without further
271 confirmatory studies. Additionally, our data does not include medications
272 prescribed in primary care, resulting in a potentially inaccurate representation of the
273 medication history of patients, especially prior to having a positive COVID-19 test
274 result.

275 Finally, low data coverage and bias may cause absence of statistically significant
276 associations with COVID-19 outcomes for some comorbidities or medications.
277 Therefore, no conclusions may be drawn for such cases without further
278 investigation.

279 *Conclusions*

280 This study provides an important piece of real-world evidence on associations
281 between co-morbidities and medication prescription, respectively with COVID-19
282 positivity presenting to hospital and inpatient mortality. Identifying these
283 associations can help in the crucial task of defining the vulnerable groups that may
284 benefit from more stringent social distancing especially as lockdown due to COVID-
285 19, is relaxed. Nonetheless, observations in this study have to be interpreted with
286 caution due to potential bias and confounders, and confirmatory studies will be
287 required to draw reliable conclusions.

288 Acknowledgements

289 This work uses data provided by patients and collected by the NHS as part of their
290 care and support. We believe using patient data is vital to improve health and care
291 for everyone and would, thus, like to thank all those involved for their contribution.

292 Special thanks are due to the Chelsea and Westminster (CW) COVID-19 AICU
293 Consortium, comprising all critical care personnel who were part of the delivery of
294 care during the COVID444 19 pandemic as follows: CW Anaesthetics Consultants,
295 Critical Care Consultants, Trainees & Fellows from ICU, Anaesthesia, and seconded
296 to ICU from other specialities, Surgeons, the supporting Respiratory and ED
297 Physicians, Operating Department Practitioners and CW Critical Care Nurses. This
298 united approach to an unprecedented clinical condition was critical not only to the
299 management of the patients but also to our ability to document and collate the key
300 data in a timely manner to support this analysis.

301 Also, a special thank you to Trystan Hawkin, Chris Chaney from CWplus, the
302 Planned Care Clinical Division managers, porters, domestic personnel and the CW
303 local community who without hesitation have supported the National Healthcare
304 System throughout the COVID-19 pandemic.

305 Compliance with ethical guidelines

306 All methods were performed in accordance with the relevant guidelines and
307 regulations.

308 The study was approved by the IG management team of Sensyne Health plc and
309 Chelsea & Westminster NHS Foundation Trust under the Strategic Research
310 Agreement (SRA) and relative Data Sharing Agreements (DSAs) signed by the NHS
311 Trust and Sensyne Health plc on 25th July 2018.

312 All analyses were conducted on data with no personal identifying information.
313 Therefore, informed consent was waived by the ethics committee of the Chelsea &
314 Westminster NHS Foundation Trust, which provided ethical approval for the study.

315 **References**

- 316 Atallah, B., Mallah, S. I. & AlMahmeed, W., 2020. Anticoagulation in COVID-19.
317 *European Heart Journal - Cardiovascular Pharmacotherapy*, p. pva036.
- 318 Chen, T. et al., 2020. Clinical characteristics of 113 deceased patients with
319 coronavirus disease 2019: retrospective study. *BMJ*, Volume 368, p. m1091.
- 320 Cure, E. & Cure, M. C., 2020a. Comment on “Should COVID-19 Concern
321 Nephrologists? Why and to What Extent? The Emerging Impasse of
322 Angiotensin Blockade”. *Nephron Clinical Practice*, Volume 144, pp. 251-252.
- 323 Cure, E. & Cure, M. C., 2020b. Angiotensin-converting enzyme inhibitors and
324 angiotensin receptor blockers may be harmful in patients with diabetes
325 during COVID-19 pandemic. *Diabetes & Metabolic Syndrome: Clinical
326 Research & Reviews*, 14(4), pp. 349-350.
- 327 Perico, L., Benigni, A. & Remuzzi, G., 2020. Should COVID-19 Concern
328 Nephrologists? Why and to What Extent? The Emerging Impasse of
329 Angiotensin Blockade. *Nephron Clinical Practice*, pp. 1-9.
- 330 Quan, H. et al., 2005. Coding Algorithms for Defining Comorbidities in ICD-9-CM
331 and ICD-10 Administrative Data. *Medical Care*, 43(11), pp. 1130-1139.
- 332 Tang, N. et al., 2020. Anticoagulant treatment is associated with decreased
333 mortality in severe coronavirus disease 2019 patients with coagulopathy.
334 *Journal of Thrombosis and Haemostasis*, 18(5), pp. 1094-1099.
- 335 Vizcaychipi, M. P. et al., 2020. Increase in COVID-19 inpatient survival following
336 detection of Thromboembolic and Cytokine storm risk from the point of
337 admission to hospital by a near real time Traffic-light System (TraCe-Tic). *The
338 Brazilian Journal of Infectious Diseases*, In Press(10.1016/j.bjid.2020.07.010).
- 339 Wang, K.-w. et al., 2020. Epidemiology of 2019 novel coronavirus in Jiangsu
340 Province, China after wartime control measures: A population-level
341 retrospective study. *Travel Medicine and Infectious Disease*.
- 342 Williams, B. & Zhang, Y., 2020. Hypertension, renin–angiotensin–aldosterone
343 system inhibition, and COVID-19. *LANCET*, 395(10238), pp. 1671-1673.

344 Wu, Z. & McGoogan, J. M., 2020. Characteristics of and Important Lessons From
345 the Coronavirus Disease 2019 (COVID-19) Outbreak in China. *JAMA*, 323(12),
346 pp. 1239-1242.

347 Yang, J. et al., 2020. Prevalence of Comorbidities and Its Effects in Patients
348 Infected With SARS-CoV-2: A Systematic Review and Meta-Analysis. *Int J*
349 *Infect Dis.*, Volume 94, pp. 91-95.

350